cd99l2 Antibody

What is CD99L2 and why are antibodies against it important for inflammation research?

CD99L2 (CD99-like 2) is a highly glycosylated 52 kDa type-1 membrane protein that plays a critical role in leukocyte transendothelial migration (TEM). It is constitutively expressed at the borders of endothelial cells and on the surface of leukocytes . CD99L2 shares approximately 32% amino acid identity with CD99, another known regulator of TEM .

CD99L2 antibodies are valuable research tools because they can:

• Block the influx of neutrophils and monocytes into inflammation sites in vivo

• Help elucidate the specific step in TEM regulated by CD99L2

• Enable investigation of inflammatory conditions like experimental autoimmune encephalomyelitis (EAE)

Research has demonstrated that inhibiting CD99L2 using function-blocking antibodies significantly reduces leukocyte recruitment to inflammation sites , making these antibodies essential for studying inflammatory processes.

How does CD99L2 differ from other adhesion molecules involved in leukocyte transmigration?

CD99L2 regulates a unique, sequential step in transendothelial migration that occurs between PECAM and CD99 involvement, rather than operating in parallel or redundantly with these molecules . Key distinguishing features include:

CD99L2 uniquely participates in helping leukocytes overcome the endothelial basement membrane, representing a distinct control point in the extravasation cascade .

What are the major applications of CD99L2 antibodies in research?

CD99L2 antibodies can be utilized across multiple research applications:

Additionally, CD99L2 antibodies are invaluable for:

• Studying neuroinflammation models like EAE

• Investigating the role of CD99L2 in various acute and chronic inflammatory diseases

• Examining leukocyte-endothelial interactions

How can I confirm the specificity of my CD99L2 antibody?

Confirming antibody specificity is crucial for reliable research outcomes. Recommended approaches include:

• Positive controls: Use cell lines known to express CD99L2, such as HUVEC cells

• Negative controls: Compare with CD99L2 knockout cells or tissues from CD99L2-deficient mice

• Antigen competition assay: Pre-incubate antibody with recombinant CD99L2 protein before staining

• Multiple antibody validation: Use antibodies targeting different epitopes of CD99L2

• Molecular weight verification: Confirm the observed molecular weight matches the expected size (approximately 40 kDa observed vs. 28 kDa calculated due to glycosylation)

• Knockdown validation: Compare staining between wild-type and CD99L2 knockdown samples

What is the optimal protocol for using CD99L2 antibodies in Western blotting?

For optimal Western blot results with CD99L2 antibodies, follow this protocol adapted from validated research:

Sample Preparation:

• Use HUVEC cells as a positive control

• Lyse cells in RIPA buffer containing protease inhibitors

• Determine protein concentration using Bradford or BCA assay

Gel Electrophoresis and Transfer:

• Load 20-50 μg of protein per lane

• Use 10-12% SDS-PAGE gels

• Transfer to PVDF membrane (preferred over nitrocellulose for glycoproteins)

Antibody Incubation:

• Block with 5% non-fat milk in TBST for 1 hour at room temperature

• Incubate with primary CD99L2 antibody at 1:500-1:2000 dilution in blocking buffer overnight at 4°C

• Wash 3-5 times with TBST

• Incubate with appropriate HRP-conjugated secondary antibody

Detection:

• Expect to observe a band at approximately 40 kDa (rather than the calculated 28 kDa) due to glycosylation

• Use ECL substrate for detection

Special Considerations:

• CD99L2 is heavily glycosylated, which affects migration on SDS-PAGE

• Sample deglycosylation may be necessary for specific experiments

How should I optimize immunostaining protocols for CD99L2?

For optimal immunostaining of CD99L2 in cells and tissues:

Cell Fixation Options:

• Ice-cold methanol fixation has been validated for HeLa cells

• 4% paraformaldehyde (PFA) fixation is also suitable for most applications

Tissue Fixation:

• 4% PFA fixation followed by paraffin embedding or frozen sectioning

• For CNS tissues, perfusion fixation is recommended before processing

Staining Protocol:

• For fixed cells: Permeabilize with 0.1-0.2% Triton X-100 if using PFA fixation (not needed for methanol)

• Block with 5-10% normal serum (matching secondary antibody species) for 1 hour

• Incubate with CD99L2 antibody at 1:500 dilution overnight at 4°C

• Wash 3-5 times with PBS

• Incubate with fluorophore-conjugated secondary antibody

• Counterstain nuclei with Hoechst 33342 or DAPI

• Mount and image

Co-staining Recommendations:

• CD99L2 can be co-stained with endothelial markers (CD31/PECAM-1)

• For leukocyte studies, combine with leukocyte subset markers

• For TEM visualization, combine with basement membrane markers

What are the key considerations when using CD99L2 antibodies in functional blocking studies?

When using CD99L2 antibodies for functional blocking in inflammation models:

Antibody Selection:

• Use validated function-blocking antibodies (not all CD99L2 antibodies block function)

• Consider polyclonal antibodies designed against the extracellular domain of CD99L2

Experimental Design:

• In vitro studies:

  • Pre-incubate cells with antibody (10-50 μg/ml) before transmigration assays

  • Include isotype controls at matching concentrations

  • Monitor for non-specific effects on cell viability

• In vivo studies:

  • Administer antibody intravenously or intraperitoneally

  • Typical doses range from 1-5 mg/kg body weight

  • Consider timing: prophylactic vs. therapeutic administration

  • Include appropriate controls (isotype, vehicle)

Model-Specific Considerations:

• For peritonitis models: administer antibody before thioglycollate challenge

• For EAE models: consider repeated dosing schedule throughout disease course

• For intravital microscopy: local administration may be appropriate

Validation of Blocking:

• Confirm reduced leukocyte infiltration using flow cytometry or histology

• Compare results with CD99L2-deficient mice for validation

How can I develop an ELISA system for detecting CD99L2?

Developing a reliable ELISA system for CD99L2 requires careful consideration of several factors:

Sandwich ELISA Approach:

• Coat 96-well plates with anti-CD99L2 antibody (5-10 μg/ml) in carbonate buffer (pH 9.6)

• Block with 1-5% BSA in PBS

• Add samples and standards (recombinant CD99L2 for standard curve)

• Detect with biotinylated anti-CD99L2 antibody targeting a different epitope

• Develop with streptavidin-HRP and appropriate substrate

Key Optimization Steps:

• Test multiple antibody pairs to identify optimal capture/detection combinations

• Consider using L2-Fc chimera as a standard (as described in the literature)

• Validate using supernatant from cells known to express CD99L2

Verification Method:
A standard sandwich ELISA to measure CD99L2-Fc has been described:

• Coat plates with anti-human Fc

• Use serial dilutions of human gamma globulin for standard curve (0-100 ng/ml)

• Detect with anti-human Fc and amplify with HRP-conjugated secondary antibody

• Develop using AZTBS substrate and read at 405 nm

How can CD99L2 antibodies help elucidate the sequential steps of transendothelial migration?

CD99L2 antibodies are powerful tools for dissecting the complex process of transendothelial migration (TEM):

Experimental Approaches:

• Sequential blocking studies:

  • Block PECAM-1, CD99L2, and CD99 individually or in combination

  • Analyze where leukocytes accumulate during TEM

  • Research shows CD99L2 regulates a step between PECAM and CD99 function

• Live-cell imaging with fluorescently-labeled antibodies:

  • Track the temporal dynamics of CD99L2 during TEM

  • Combine with membrane markers to visualize diapedesis

• Lateral border recycling compartment (LBRC) recruitment analysis:

  • Use CD99L2 antibodies alongside markers of the LBRC

  • Research demonstrates CD99L2 promotes transmigration by recruiting the LBRC to TEM sites specifically downstream of PECAM initiation

Key Findings from Sequential Blocking:
Research using CD99L2 antibodies has revealed that:

• PECAM functions first in the TEM cascade

• CD99L2 functions in an intermediate step

• CD99 mediates the final step

• These steps operate sequentially rather than redundantly

How do CD99L2 antibodies contribute to our understanding of neuroinflammation?

CD99L2 antibodies have provided significant insights into neuroinflammation mechanisms:

Experimental Applications in Neuroinflammation:

• Blood-brain barrier (BBB) studies:

  • CD99L2 antibodies help visualize the interaction between leukocytes and BBB endothelium

  • Can be used to track leukocyte accumulation at specific stages of diapedesis

• EAE model investigations:

  • CD99L2 gene inactivation inhibits leukocyte entry into the CNS during active MOG35-55-induced EAE

  • Antibodies can be used to study the disease mechanism in wild-type animals

  • Help identify the specific stage of extravasation affected (diapedesis through endothelial basement membrane)

• Therapeutic potential exploration:

  • Function-blocking antibodies against CD99L2 can be tested for their ability to alleviate neuroinflammation

  • Research shows CD99L2 deficiency inhibits leukocyte entry into the CNS and ameliorates neuroinflammation

Key Findings:

• CD99L2 antibody-based studies revealed that CD99L2 deficiency leads to:

  • Reduced number of perivascular cuffs around CNS vessels

  • Fewer inflammatory foci and sites of demyelination

  • Lower expression levels of pro-inflammatory cytokines

  • Accumulation of leukocytes between endothelial cells and the underlying basement membrane

What are the technical challenges in developing neutralizing antibodies against CD99L2?

Developing effective neutralizing antibodies against CD99L2 presents several technical challenges:

Epitope Selection Challenges:

• CD99L2 is heavily glycosylated (observed MW 40-52 kDa vs. calculated 28 kDa)

• Post-translational modifications, including O-glycosylation, may mask critical epitopes

• Functional domains must be targeted for effective neutralization

• Extracellular domain (Val20-Ala188) has been successfully targeted in previous studies

Production and Validation Hurdles:

• Antibody production approaches:

  • Recombinant CD99L2 production from CHO cells for immunization

  • L2-Fc chimera creation for screening and validation

  • Multiple epitope targeting may be necessary

• Validation requirements:

  • Confirmation of binding to native protein on cell surface

  • Demonstration of functional blocking in vitro

  • In vivo efficacy testing in inflammation models

  • Comparison with CD99L2 knockout phenotypes

Species Cross-Reactivity Issues:

• Human and mouse CD99L2 share significant homology but are not identical

• Species-specific epitopes may necessitate separate antibody development for human and mouse studies

• Cross-reactivity testing is essential for translational research

How can CD99L2 antibodies be used to study the differential roles of endothelial versus leukocyte CD99L2?

Distinguishing the roles of CD99L2 on different cell types requires sophisticated experimental approaches:

Cell-Specific Blocking Strategies:

• Selective blocking of endothelial CD99L2:

  • Pre-treat endothelial monolayers with CD99L2 antibodies before adding leukocytes

  • Wash away excess antibody to ensure only endothelial CD99L2 is blocked

  • Use Tie2-Cre driven gene inactivation models as validation controls

• Selective blocking of leukocyte CD99L2:

  • Pre-treat isolated leukocytes with CD99L2 antibodies

  • Wash cells before adding to untreated endothelium

  • Compare results with leukocyte-specific CD99L2 knockout models

Mixed Cell Population Approaches:

• Create chimeric mice by transferring CD99L2-deficient bone marrow to wild-type mice (and vice versa)

• Use cell-specific antibody labeling to distinguish the contribution of each cell type

• Compare with results from total CD99L2 knockout or antibody blockade

Homophilic Interaction Studies:

• CD99L2 can function as a homophilic adhesion molecule

• Antibodies can disrupt these interactions to determine their importance in TEM

• Results from L cell fibroblast studies showed CD99L2 transfection imparted divalent cation-dependent, homophilic adhesion capacity